From protein function to cellular health
Unique approach
Most drugs inhibit proteins that contribute to disease. What if we could instead enhance proteins that can restore health?
Restore needed levels of a key protein by extending its lifespan
Relocate a misplaced protein to where it's needed in the cell
Change a protein's activity by altering its structure or interactions
Broad potential
ENTAC™ medicines enhance the function of key proteins to treat a broad range of diseases.
Target previously undruggable pathways
Address hard-to-treat genetic disorders
Treat common complex diseases
Powerful platform
Our Encompass™ platform provides an end-to-end system for efficiently creating ENTACs.
Identify targets amenable to ENTAC intervention
Validate ENTAC-disease hypothesis
Design and optimize target-specific ENTACs
Our science
ENTACs are molecular matchmakers, bringing together target proteins with enzymes called DUBs. By recruiting the right DUB for each target, ENTACs harness the natural ability of DUBs to enhance protein function.
Target protein
Critical proteins that are in short supply, are in the wrong location, or have suboptimal activity
ENTAC
Enhancement-targeting chimeras are orally available, bifunctional small molecules
Dub
Deubiquitinases selectively remove ubiquitin molecules from target proteins
Who we are
We are scientists, entrepreneurs, drug creators, and problem solvers, all inspired by the idea that even when you’re ill there’s something intact within your cells that can help you get well.
Led by executives who have successfully transformed ideas into medicines, guided by scientific founders who have helped define the DUB field, and backed by investors with the courage to push drug development’s frontiers, we’re working together to bring ENTACs to the patients who need them most.
Read more about our team
Latest news & publications
02/07/2023 News
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Guiding a young, groundbreaking company to maturity calls for a leader who can strike the right balance between oversight and support. Victoria Richon is hoping to provide just that as the new CEO of Entact Bio, a preclinical biotech that came out of stealth in December...
01/06/2023 News
Entact Bio: Victoria Richon, CEO
The language of drug development is often militaristic. Medicinal chemists build arsenals of small molecules—looking for inhibitors or “warheads” that can hit “targets” and “combat” disease. Block, eliminate, disrupt, halt. For decades, drug makers have sought “magic bullets” that can precisely destroy ...
12/07/2022 News
Entact Bio launches with $81 million to enhance protein function
When proteins within the body get tagged with a molecule called ubiquitin, they are essentially marked for destruction. But they can be saved; a deubiquitinase enzyme can remove the ubiquitin, keeping the protein intact. That, at least in part, is what Entact Bio aims to do...
12/06/2022 News
Biotech cofounded by Dana-Farber scientists launches with $81m for new approach to drugs
A small startup in Watertown has raised millions of dollars for early-stage research on a potentially powerful new idea that’s beginning to take hold in the biotech industry: designing drugs to enhance or prolong the function of helpful proteins that ward off disease. If successful, the approach could lead to new therapie...
Privacy & Terms of Use
Copyright © 2023